Clinical Trials

900 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT07213674 2026-04-16

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

750 enrolled

Prostatic Neoplasms

NCT03661320 2026-04-15

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

855 enrolled

Urinary Bladder Neoplasms

NCT03967977 2026-04-15

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

420 enrolled

Carcinoma, Transitional Cell

NCT06136650 2026-04-15

MK-5684-004

1,314 enrolled

Prostatic Neoplasms

NCT03091192 2026-04-14

Savolitinib vs. Sunitinib in MET-driven PRCC.

60 enrolled 15 charts

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

NCT03528694 2026-04-14

POTOMAC

1,018 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT04960709 2026-04-14

VOLGA

712 enrolled

Urinary Bladder Neoplasms

NCT06122584 2026-04-14

Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

380 enrolled

Prostatic Neoplasms

NCT07225946 2026-04-14

KLK2-PASenger

800 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT01946204 2026-04-13

SPARTAN

1,207 enrolled 15 charts 2 FDA

Prostatic Neoplasms

NCT02257736 2026-04-13

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

982 enrolled 15 charts

Prostatic Neoplasms

NCT02489318 2026-04-13

TITAN

1,052 enrolled 13 charts 2 FDA

Prostatic Neoplasms

NCT02531516 2026-04-13

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

1,503 enrolled

Prostatic Neoplasms

NCT03390504 2026-04-13

THOR

629 enrolled 32 charts 1 FDA

Urothelial Cancer

NCT03748641 2026-04-13

MAGNITUDE

765 enrolled 16 charts 2 FDA

Prostatic Neoplasms, Castration-Resistant

NCT03767244 2026-04-13

PROTEUS

2,517 enrolled

Prostatic Neoplasms

NCT04497844 2026-04-13

AMPLITUDE

696 enrolled 15 charts 3 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT04557059 2026-04-13

PRIMORDIUM

693 enrolled

Prostatic Neoplasms

NCT04658862 2026-04-13

SunRISe-2

518 enrolled

Urinary Bladder Neoplasms

NCT05714202 2026-04-13

SunRISe-3

1,135 enrolled

Urinary Bladder Neoplasms

NCT06211764 2026-04-13

SunRISe-5

272 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06319820 2026-04-13

MoonRISe-1

641 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06925737 2026-04-13

MK-2400-001

1,440 enrolled

Prostatic Neoplasms

NCT07164443 2026-04-13

KLK2-comPAS

663 enrolled

Metastatic Castration-resistant Prostate Neoplasms

NCT07227402 2026-04-13

LITESPARK-033

904 enrolled

Carcinoma, Carcinoma, Renal Cell

NCT07419295 2026-04-13

TroFuse-031

590 enrolled

Phase 3 Not yet recruiting

Urinary Bladder Neoplasms

NCT07526792 2026-04-13

SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

406 enrolled

Carcinoma, Transitional Cell

NCT06056830 2026-04-09

CLARIFY

383 enrolled

Prostatic Neoplasms

NCT06970847 2026-04-09

AMPLIFY

220 enrolled

Prostatic Neoplasms

NCT06136624 2026-04-08

OMAHA-003

1,310 enrolled

Prostate Cancer Metastatic

NCT06235151 2026-04-08

Solar-Stage

439 enrolled

Prostatic Neoplasms

NCT04821622 2026-04-07

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

599 enrolled

Prostatic Neoplasms

NCT05911295 2026-04-07

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

412 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05009290 2026-04-03

A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy

Phase 3 Terminated

391 enrolled

Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

NCT06120491 2026-04-03

EvoPAR-PR01

1,800 enrolled

Prostatic Neoplasms

NCT04493853 2026-04-01

CAPItello-281

1,012 enrolled

Prostatic Neoplasms

NCT07011719 2026-04-01

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

720 enrolled

Clear-cell metastatic renal cell carcinoma, Kidney Neoplasms

NCT07197580 2026-04-01

LUTEON

40 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms, Recurrence

NCT03815643 2026-03-31

Avelumab Program Rollover Study

GenitourinaryGynecologicThoracic

205 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Ovarian Neoplasms

NCT07405164 2026-03-31

MK-6482-043

450 enrolled

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT06510374 2026-03-30

ABLE-32

454 enrolled

Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06960577 2026-03-30

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

150 enrolled

Urinary Bladder Neoplasms

NCT07028853 2026-03-30

MEVPRO-3

1,000 enrolled

Prostatic Neoplasms

NCT04660344 2026-03-27

IMvigor011

761 enrolled

Phase 3 Not yet recruiting

Muscle-invasive Bladder Cancer

NCT07489495 2026-03-24

LITESPARK-034

758 enrolled

Carcinoma, Renal Cell

NCT04689828 2026-03-23

PSMAfore

469 enrolled 11 charts 3 FDA

Prostatic Neoplasms

NCT05037279 2026-03-20

EVER

540 enrolled

Urinary Bladder Neoplasms, Recurrence

NCT04338269 2026-03-19

CONTACT-03

Phase 3 Terminated

522 enrolled 22 charts